Detailed explanation of the functions, efficacy and indications of ritexitinib (Lefenox)

1. Drug introduction and mechanism of action

Ritlecitinib (Ritlecitinib) is an oral small molecule inhibitor that is a selective JAK3 inhibitor and has a certain inhibitory effect on TEC family kinases. The JAK-STAT signaling pathway plays a key role in a variety of immune responses and inflammatory responses, while the TEC family of kinases plays an important role in lymphocyte signal transduction and the pathogenesis of autoimmune diseases. Ritexitinib regulates abnormal immune responses by specifically inhibiting JAK3 and TEC family kinases, inhibits excessive activation of inflammatory signals, and helps improve clinical symptoms of immune-related diseases.

Compared with traditional non-selective JAK inhibitors, ritexitinib’s highly selective effect on JAK3 reduces the risk ofJAK1 and JAK2 thereby maintaining drug efficacy while reducing immunosuppression-related side effects, such as hematological toxicity and risk of infection. This unique mechanism enables it to demonstrate significant efficacy and good safety in the treatment of a variety of autoimmune diseases and inflammatory diseases.

2. Main indications

Ritexitinib is currently mainly used for the treatment of immune-mediated alopecia and some autoimmune diseases. Its main indications include:

1.Alopecia Areata, AA:

Alopecia areata is an autoimmune disease in which the patient's immune system abnormally attacks hair follicles, causing partial or complete hair loss.

Clinical studies have shown that ritexitinib can block immune cells from attacking hair follicles by inhibiting the JAK3 signaling pathway, thereby promoting hair regeneration. The treatment cycle is generally 12 to 24 weeks. Some patients can observe partial hair regeneration in the early stages of treatment. As the treatment course is extended, the curative effect will further appear.

2.Alopecia totalis/Alopecia universalis (Alopecia Totalis/Universalis, AT/AU):

For patients with alopecia totalis or hair loss all over the body, traditional treatments have limited efficacy. Ritexitinib is effective through its high selectivityJAK3The inhibitory effect can help the immune system restore tolerance to hair follicles. Some clinical trials have shown that the hair regeneration rate of patients is significantly higher than that of the placebo group, especially when used early or combined with topical treatment, the effect is better.

3.Potential indications for other autoimmune diseases:

BecauseJAK3/TEC signaling plays an important role in a variety of immune diseases, ritexitinib is undergoing clinical trials to evaluate its therapeutic potential in diseases such as rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. Preliminary data show that it has certain efficacy in improving inflammatory indicators and clinical symptoms, but more clinical trials are needed to verify it.

3. Clinical efficacy and research data

In multiple Phase II and III clinical trials, ritixitinib has shown significant efficacy in patients with alopecia areata and alopecia totalis. For example:

1.Objective hair loss improvement rate (SALT score): Studies show that among patients treated with ritexitinib, about 50%~70% The hair regeneration of patients with moderate to severe alopecia areata reached more than 50% within 24 weeks, while the placebo group only achieved about 10%~15% hair regeneration.

2.Onset of effect: Some patients can observe hair germination within 4~8 weeks of treatment, and 12~24 weeks is the significant curative effect period.

3.Improvement of quality of life: Hair regeneration significantly improves patients' self-image and psychological state, and reduces anxiety and depression symptom scores.

In addition, ritexitinib is well tolerated by patients, and most adverse reactions are mild to moderate, commonly including mild upper respiratory tract infection, headache, mild elevation of liver enzymes, or mild changes in blood lipids. The incidence of serious hematological toxicities and infectious events was significantly lower compared with non-selective JAK inhibitors.

4. Medication guidance and precautions

1. Medication dosage and cycle:

Adult patients generally take a fixed dose orally, 1 to 2 times a day, and adjust the dose according to body weight and condition.

The treatment cycle is generally 3~6 months, and the dose may be adjusted or discontinued based on hair regeneration and side effects.

2.Monitoring and security:

Liver and kidney function, blood routine, and infection risk should be assessed before treatment;

During treatment, blood routine, liver and kidney function should be reviewed regularly, and potential adverse reactions should be monitored;

In the event of serious infection, significant elevation of liver enzymes, or abnormal blood indicators, dose adjustment or medication suspension should be considered.

3. Medication precautions:

Avoid co-administration with potentCYP3A4 inhibitors or inducers to avoid affecting blood concentration;

Not suitable for pregnant and lactating women;

It should be used with caution in children and adolescent patients as clinical data are currently limited.

Combined treatment and individualized plan:

Clinically, it can be used in combination with local glucocorticoids and local immunotherapy to enhance the hair regeneration effect;

Developing an individualized treatment plan based on the patient's hair loss type, course, and concomitant diseases can maximize efficacy and reduce risks.

Ritlecitinib (Ritlecitinib) is a selective JAK3 inhibitor with an innovative mechanism. It is mainly used to treat autoimmune hair loss diseases such as alopecia areata and alopecia totalis. It achieves hair regeneration by precisely regulating immune signaling pathways, and has shown significant efficacy and good safety in clinical studies. With the accumulation of clinical data and the exploration of more indications, ritixitinib is expected to expand into more areas of treatment for autoimmune diseases and provide patients with safer and more efficient targeted treatment options.

Reference link:https://www.drugs.com